92 related articles for article (PubMed ID: 11565264)
1. [Behavior of antigen-specific CD8+ T cells in Epstein-Barr virus-related disease].
Kuzushima K
Uirusu; 2001 Jun; 51(1):43-9. PubMed ID: 11565264
[No Abstract] [Full Text] [Related]
2. [Quantitative analysis of Epstein-Barr virus (EBV)-specific CD8+ T lymphocytes in EBV-related diseases].
Kuzushima K
Rinsho Ketsueki; 2000 Jun; 41(6):487-90. PubMed ID: 10921347
[No Abstract] [Full Text] [Related]
3. Control of Epstein-Barr virus load and lymphoproliferative disease by maintenance of CD8+ T lymphocytes in the T lymphocyte-depleted graft after bone marrow transplantation.
Torre-Cisneros J; Román J; Torres A; Herrera C; Caston JJ; Rivero A; Mingot E; Rojas R; Martín C; Martínez F; Gómez P
J Infect Dis; 2004 Nov; 190(9):1596-9. PubMed ID: 15478063
[TBL] [Abstract][Full Text] [Related]
4. Epstein-Barr virus-specific cytotoxic T-lymphocytes for adoptive immunotherapy of post-transplant lymphoproliferative disease.
Burns DM; Crawford DH
Blood Rev; 2004 Sep; 18(3):193-209. PubMed ID: 15183903
[TBL] [Abstract][Full Text] [Related]
5. Adoptive immunotherapy for Epstein-Barr virus-associated lymphoproliferative disorders complicating marrow allografts.
O'Reilly RJ; Small TN; Papadopoulos E; Lucas K; Lacerda J; Koulova L
Springer Semin Immunopathol; 1998; 20(3-4):455-91. PubMed ID: 9870257
[No Abstract] [Full Text] [Related]
6. [Epstein-Barr virus (1)--Establishment of the infection and dynamics of virus--specific T cell responses].
Kuzushima K
Uirusu; 2002 Jun; 52(1):123-7. PubMed ID: 12227160
[No Abstract] [Full Text] [Related]
7. Epstein-Barr virus-specific T-cell cytotoxicity is mediated through the perforin pathway in patients with lymphoproliferative disorders after allogeneic bone marrow transplantation.
Yoshimi A; Tsuge I; Namizaki H; Hoshino Y; Kimura H; Takahashi Y; Watanabe N; Kuzushima K; Kojima S
Br J Haematol; 2002 Mar; 116(3):710-5. PubMed ID: 11849237
[TBL] [Abstract][Full Text] [Related]
8. Epstein-Barr virus (EBV)-associated post-transplantation lymphoproliferative disorder simultaneously affecting both B and T cells after allogeneic bone marrow transplantation.
Chuhjo T; Yachie A; Kanegane H; Kimura H; Shiobara S; Nakao S
Am J Hematol; 2003 Apr; 72(4):255-8. PubMed ID: 12666136
[TBL] [Abstract][Full Text] [Related]
9. Early intervention in post-transplant lymphoproliferative disorders based on Epstein-Barr viral load.
Hoshino Y; Kimura H; Kuzushima K; Tsurumi T; Nemoto K; Kikuta A; Nishiyama Y; Kojima S; Matsuyama T; Morishima T
Bone Marrow Transplant; 2000 Jul; 26(2):199-201. PubMed ID: 10918431
[TBL] [Abstract][Full Text] [Related]
10. [Characterization of Epstein-Barr virus-specific CD8+ T cells in infectious mononucleosis].
Kuzushima K
Rinsho Ketsueki; 2001 Jun; 42(6):458-63. PubMed ID: 11505522
[No Abstract] [Full Text] [Related]
11. T cell repertoire and Epstein-Barr virus-specific T cell response in chronic active Epstein-Barr virus infection: a case study.
Gallot G; Hamidou MA; Clémenceau B; Gaschet J; Tiberghien P; Ferrand C; Vivien R; Barbarot S; Coste-Burel M; Moreau A; Vié H
Clin Immunol; 2006 Apr; 119(1):79-86. PubMed ID: 16386957
[TBL] [Abstract][Full Text] [Related]
12. Impact of primary Epstein-Barr virus infection on timing of transplantation.
Smets F
Pediatr Transplant; 2006 Dec; 10(8):869-71. PubMed ID: 17096751
[No Abstract] [Full Text] [Related]
13. Epstein-Barr virus T-cell immunity despite rituximab.
Nehring AK; Dua U; Mollee P; Gill D; Grimmett K; Khanna R; Moss D; Gandhi MK
Br J Haematol; 2007 Feb; 136(4):628-32. PubMed ID: 17223914
[TBL] [Abstract][Full Text] [Related]
14. Epstein-Barr virus-associated lymphoproliferative disease after allogeneic haematopoietic stem cell transplantation: molecular monitoring and early treatment of high-risk patients.
Meijer E; Cornelissen JJ
Curr Opin Hematol; 2008 Nov; 15(6):576-85. PubMed ID: 18832928
[TBL] [Abstract][Full Text] [Related]
15. Advanced therapeutic and prophylactic strategies for Epstein-Barr virus infection in immunocompromised patients.
Okano M; Gross TG
Expert Rev Anti Infect Ther; 2007 Jun; 5(3):403-13. PubMed ID: 17547505
[TBL] [Abstract][Full Text] [Related]
16. [Cell therapy for Epstein-Barr virus-associated disease].
Kuzushima K
Nihon Rinsho; 2006 Mar; 64 Suppl 3():678-81. PubMed ID: 16615558
[No Abstract] [Full Text] [Related]
17. Control of virus-induced lymphoproliferation: Epstein-Barr virus-induced lymphoproliferation and host immunity.
Rooney CM; Smith CA; Heslop HE
Mol Med Today; 1997 Jan; 3(1):24-30. PubMed ID: 9021739
[TBL] [Abstract][Full Text] [Related]
18. Immune-cell treatment of Epstein--Barr-virus-associated lymphoproliferative disorders.
Swinnen LJ
Best Pract Res Clin Haematol; 2006; 19(4):839-47. PubMed ID: 16997187
[TBL] [Abstract][Full Text] [Related]
19. Frequency of CD8(+) T lymphocytes specific for lytic and latent antigens of Epstein-Barr virus in healthy virus carriers.
Benninger-Döring G; Pepperl S; Deml L; Modrow S; Wolf H; Jilg W
Virology; 1999 Nov; 264(2):289-97. PubMed ID: 10562493
[TBL] [Abstract][Full Text] [Related]
20. Antigen-specific T cells for the treatment of infections after transplantation.
Einsele H
Hematol J; 2003; 4(1):10-7. PubMed ID: 12692515
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
